• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Tariquidar methanesulfonate, hydrate Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754009

Tariquidar methanesulfonate, hydrate is a potent and specific P-glycoprotein (P-gp) inhibitor(Kd of 5.1nM). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Tariquidar methanesulfonate, hydrate, Inhibitor
Full Product Name
Tariquidar methanesulfonate, hydrate
Product Synonym Names
XR9576 methanesulfonate; hydrate
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
892.99
Solubility
DMSO: 296mg/mL (331.47mM)
H2O: 5mg/mL (5.60mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C40H52N4O15S2
SMILES
O=C(C1=CC2=CC=CC=C2N=C1)NC3=CC(OC)=C(OC)C=C3C(NC4=CC=C(CCN5CC6=C(C=C(OC)C(OC)=C6)CC5)C=C4)=O.CS(=O)(O)=O.CS(=O)(O)=O.O.O.O
CAS Number
625375-83-9
Target & IC50
P-gp: ic50 5.1nM (ki)
In Vitro
In mice with intrinsically resistant MC26 colon tumors, co-administration of hydrated Tariquidar mesylate (XR9576 mesylate, hydrate) can enhance the antitumor activity of doxorubicin without significantly increasing toxicity; maximum potentiation is observed at 2.5-4.0mg/kg dosed either i.v. or p.o. In addition, coadministration of Tariquidar (6-12mg/kg p.o.) fully restores the antitumor activity of Paclitaxel, Etoposide, and Vincristine against two highly resistant MDR human tumor xenografts (2780AD, H69/LX4) in nude mice. Tariquidar is found to also significantly potentiate the antitumor activity of doxorubicin against s.c. MC26 tumors in vivo[2].

Product References and Citations for Tariquidar methanesulfonate, hydrate, inhibitor

Martin C, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol, 1999, 128(2), 403-411.
Martin C, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol, 1999, 128(2), 403-411.
Mistry P, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 2001, 61(2), 749-758.
Mistry P, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 2001, 61(2), 749-758.
Vraka C, et al. A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. Nucl Med Biol. 2018 Feb 14;60:29-36.
Vraka C, et al. A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. Nucl Med Biol. 2018 Feb 14;60:29-36.

Other Notes

Small volumes of Tariquidar methanesulfonate, hydrate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Tariquidar methanesulfonate, hydrate purchase

MBS5754009 is an inhibitor targeting Tariquidar methanesulfonate, hydrate.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000